1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Anti Angiogenesis: new trials by email Literature Review of Anti Angiogenesis trials Research Report on Anti Angiogenesis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC Immunochemotherapy combined with antiangiogenic, Immunochemotherapy - Non-Small Cell Lung Cancer, Anti Angiogenesis | Phase 2 | Not yet recruiting | Tang-Du Hospital | 178 | 2024-06-30 | 2024-06-26 |
Carcinoma, Non-Small-Cell Lung (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Albumin-Bound Paclitaxel (1) · Angiogenesis Inhibitors (1) · Carboplatin (1) · Cisplatin (1) · Paclitaxel (1) · Pemetrexed (1) · anlotinib (1) · tislelizumab (1)
Tang-Du Hospital (1)
China (1)
Linna Liu (1)